Featured Trial
Clinical Trial Goal
To find out if the combination of isatuximab and lenalidomide is safe and works well to treat multiple myeloma that doctors consider high-risk after autologous BMT
You may be able to join this trial if you:
- Are 18 - 72 years old
- Have multiple myeloma that doctors consider high-risk
- Have had or plan to have an autologous BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Isatuximab is a monoclonal antibody that targets CD38 on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT:
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT:
- Isatuximab – Given as an intravenous (IV) infusion
- Lenalidomide - A pill that you take by mouth
You may continue treatment for up to 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial.
Locations
M D Anderson Cancer CenterRECRUITING
Houston, Texas
Contacts:
- Muzaffar Qazilbash, MD, (713) 745-3458, mqazilba@mdanderson.org
- Muzaffar Qazilbash, MD
Sponsors
collaborator: Sanofi, lead: M.D. Anderson Cancer Center
